BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis and prognosis of epilepsy.

Epilepsy is a serious neurological condition that impacts over 65M people around the world.

BioEP is a patented seizure risk score calculated from routine EEG recordings that can enable faster and more accurate diagnosis and prognosis of epilepsy.

Neuronostics is a collaborative organisation and welcomes enquiries from researchers, clinicians and commercial partners.

We are Neuronostics

Neuronostics is a fast growing med-tech company, passionate about using research to improve the lives of people with epilepsy.

We are developing a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.

Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.

We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.

Find out the latest news and information from Neuronostics.

Neuronostics win Medilink ‘Advances in Digital Healthcare’ Award

12th May 2022 We are delighted to receive the ‘Advances in Digital Healthcare Award’ in the South West at the Medilink South West Awards evening. Medilink SW had this to say ‘This... [Read More]

New Chief Technical Officer role

This is an exciting opportunity for a dynamic and proactive individual to provide technology leadership to Neuronostics at a time of significant growth. As Chief Technical Officer, you will be responsible for leading software development... [Read More]

Join us at our Epilepsy Connect networking event

In partnership with Epilepsy Action, we are holding an Epilepsy Connect networking event on the 18th May 2022 – 16.30 to 18.30 at the Nexus Centre, University of Leeds. The event will... [Read More]